Last reviewed · How we verify
Extra fine Formoterol/Beclomethasone
This combination inhaler delivers a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle and an inhaled corticosteroid (beclomethasone) to reduce airway inflammation.
This combination inhaler delivers a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle and an inhaled corticosteroid (beclomethasone) to reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Extra fine Formoterol/Beclomethasone |
|---|---|
| Also known as | Innovair |
| Sponsor | National Institute of Respiratory Diseases, Mexico |
| Drug class | Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) |
| Target | Beta-2 adrenergic receptor; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Formoterol acts as a bronchodilator by stimulating beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and airway opening. Beclomethasone is a corticosteroid that suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production, edema, and eosinophil infiltration. The extra-fine particle formulation enhances deposition in small airways.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
Key clinical trials
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
- TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients
- A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes
- Functional Respiratory Imaging Study (PHASE3)
- The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.
- Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients (PHASE2)
- Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis (PHASE4)
- Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: